SOUTH SAN FRANCISCO, CA--(Marketwired - Nov 10, 2015) - Titan Pharmaceuticals, Inc. (
The live webcast of the call may be accessed by visiting the Titan website at www.titanpharm.com . The call can also be accessed by dialing 888-428-9490 , participant code 4650396, five minutes prior to the start time. A replay of the call will be available on the company website approximately two hours after completion of the call and will be archived for two weeks.
About Titan Pharmaceuticals
Titan Pharmaceuticals Inc. (
The press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to the Company's development program and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to difficulties or delays in development, testing, regulatory approval, production and marketing of the Company's drug candidates, adverse side effects or inadequate therapeutic efficacy of the Company's drug candidates that could slow or prevent product development or commercialization, the uncertainty of patent protection for the Company's intellectual property or trade secrets, and the Company's ability to obtain additional financing. Such statements are based on management's current expectations, but actual results may differ materially due to various factors, including those risks and uncertainties mentioned or referred to in this press release.
CONTACT: Titan Pharmaceuticals, Inc.: Sunil Bhonsle, President (650) 244-4990 Investors: Stephen Kilmer (650) 989-2215 skilmer@titanpharm.com Media: Susan Thomas (650) 989-2216 sthomas@titanpharm.com